Tesamorelin Peptide Therapy
Beverly Hills, CA
Deep abdominal fat can remain stubborn even when your nutrition, exercise, and weight-loss efforts are consistent. This visceral fat sits around the internal organs, where it can affect both waistline proportions and metabolic health. It also responds differently from the softer fat located directly beneath the skin.
Tesamorelin peptide therapy at Physique26 in Beverly Hills offers a physician-guided approach to this specific body-composition concern. By encouraging your pituitary gland to release its own growth hormone, tesamorelin supports a natural signaling pathway associated with visceral fat metabolism, recovery, and lean tissue maintenance.
In clinical practice, a consistent pattern shows up. Patients lose weight—but not in the way they expected. Strength drops. Muscle softens. Metabolism slows.
What looks like success on the scale often reflects a mix of fat loss and lean mass loss.
That distinction matters.
Without hormonal regulation and a structured plan to preserve muscle, the body adapts aggressively. Energy expenditure declines. Hunger signals rise. And over time, weight regain becomes more likely.
A medical weight loss program built around GLP-1 physiology changes that equation entirely.
Tesamorelin is a prescription growth hormone-releasing hormone analog that stimulates the pituitary gland to increase the body’s natural production of growth hormone and insulin-like growth factor 1, or IGF-1. Tesamorelin is not a synthetic human growth hormone.
Tesamorelin is modeled on the body’s natural growth hormone-releasing hormone, commonly called GHRH. It has been modified to remain active longer than naturally occurring GHRH, creating a stronger and more sustained signal to the pituitary gland.
Tesamorelin works upstream within the growth hormone pathway. It encourages your body to produce and release its own growth hormone rather than supplying growth hormone directly.
Tesamorelin has the strongest clinical evidence among commonly discussed GHRH peptides for reducing visceral abdominal fat. A prescription form of tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Physician-directed use for other body-composition or wellness goals is considered off-label and requires individualized screening and monitoring.
Tesamorelin is most closely associated with reducing visceral adipose tissue, the deeper abdominal fat located around the organs. This differs from subcutaneous fat, which sits directly beneath the skin and can be pinched.
Depending on your medical eligibility and treatment plan, tesamorelin may support goals related to:
Tesamorelin is considered weight-neutral in its FDA-approved use. Its primary role is changing visceral fat distribution rather than producing broad weight loss. A patient may therefore experience a meaningful change in abdominal composition without seeing a dramatic change on the scale.
For patients whose main goal is overall weight loss or appetite control, a GLP-1 medication may be a more appropriate starting point. Physique26 can determine whether tesamorelin, a GLP-1 program, or a coordinated strategy best matches the desired outcome.
Growth hormone is released by the pituitary gland in pulses, with some of the strongest natural secretion occurring during sleep. The hypothalamus helps regulate this process by producing growth hormone-releasing hormone.
Tesamorelin acts as a GHRH analog. After binding to GHRH receptors on the pituitary gland, it signals the gland to release growth hormone. That growth hormone then stimulates the liver and other tissues to produce IGF-1.
Growth hormone and IGF-1 influence several processes connected to body composition, including:
Tesamorelin’s effect on visceral fat is its most clinically established benefit. Visceral fat is metabolically active and generally more responsive to growth hormone signaling than subcutaneous fat. In clinical trials involving adults with HIV-associated abdominal fat accumulation, tesamorelin reduced visceral adipose tissue while having less effect on the fat directly beneath the skin.
Because tesamorelin stimulates your own pituitary gland, natural feedback mechanisms remain involved in regulating growth hormone production. Its stronger and longer-lasting GHRH signal generally produces a greater increase in growth hormone and IGF-1 than sermorelin.
Tesamorelin requires careful medical selection because it affects growth hormone and IGF-1 levels. Your provider will consider your goals, laboratory results, current medications, metabolic health, and personal and family medical history.
A history of cancer, diabetes, pituitary disease, or another endocrine condition does not always produce the same treatment decision, but it does mean your provider needs a thorough understanding of your health before discussing therapy.
Physique26 uses a structured evaluation to determine whether tesamorelin fits your goals and risk profile.
Tesamorelin is generally administered into the fatty tissue of the abdomen. Injection sites should be rotated to reduce irritation. Avoid injecting into bruised, scarred, reddened, or tender skin.
Most patients can continue normal daily activities immediately after an injection. Temporary redness, itching, tenderness, or bruising may occur around the injection site.
Changes in visceral fat do not appear overnight. Early progress may be subtle and can include improvements in waist measurements, clothing fit, body proportions, or training recovery. Scale weight may remain relatively stable because tesamorelin is not primarily a general weight-loss medication.
Follow the nutrition, exercise, and medication instructions provided by Physique26.
Tesamorelin produces gradual changes. Clinical studies evaluating visceral fat commonly measured outcomes after approximately six months of treatment, although individual patients may notice changes in waistline, body composition, or recovery sooner.
Your timeline may depend on:
Physique26 tracks practical outcomes instead of relying only on scale weight. Waist measurements, clothing fit, body-composition data, strength, recovery, and laboratory findings can provide a more complete picture.
If meaningful changes are not developing, your provider will reassess the dose, diagnosis, treatment strategy, and value of continuing.
Continued treatment may be necessary to maintain changes in visceral fat. Clinical research has found that visceral fat can return after tesamorelin is discontinued, particularly when the underlying factors contributing to abdominal fat remain present.
This makes maintenance planning important. Your provider may recommend continued therapy, a defined treatment cycle, or a transition into another metabolic strategy based on your response and laboratory results.
Long-term management may include:
Physique26 continues tesamorelin only when the measurable benefit and safety profile support ongoing use.
Commonly reported side effects of prescription tesamorelin include injection-site redness or itching, joint discomfort, muscle aches, pain in the extremities, and fluid retention. Fluid retention can contribute to swelling, joint pain, or carpal tunnel symptoms.
Tesamorelin raises IGF-1 and may affect glucose control. Regular monitoring helps identify levels that become too high and allows your provider to respond to changes in fasting glucose or hemoglobin A1C.
Tesamorelin is FDA-approved in specific prescription formulations for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Use for other body-composition or wellness goals is off-label. Treatment at Physique26 includes informed consent, medical screening, individualized prescribing, and ongoing monitoring.
The cost of tesamorelin therapy depends on the prescription, treatment duration, diagnostic needs, and follow-up schedule.
Your personalized cost may include:
Physique26 reviews expected costs before treatment begins so you understand what is included in your plan. Pricing is individualized because medication needs and monitoring requirements vary.
Sermorelin and tesamorelin both stimulate natural growth hormone release through the GHRH receptor. Neither medication is human growth hormone.
Sermorelin is a shorter GHRH analog and is generally considered the milder option. Physique26 may recommend it for sleep, recovery, lean muscle support, or broader healthy-aging goals.
Tesamorelin is more potent and longer-acting. It generally produces a greater increase in growth hormone and IGF-1 and has substantially stronger clinical evidence for reducing visceral abdominal fat.
The better choice depends on your primary goal, baseline laboratory findings, medical history, and tolerance for monitoring.
Tesamorelin acts through the GHRH receptor. Ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor. Because they stimulate growth hormone through different pathways, some clinicians combine them to encourage a stronger, physiologic growth hormone pulse.
Combination therapy is not required, and strong evidence showing superior long-term outcomes remains limited. Physique26 considers combination therapy only when the expected benefit and monitoring plan make sense for the individual patient.
Tesamorelin prompts the pituitary gland to release growth hormone. Exogenous human growth hormone supplies the hormone directly and bypasses the body’s initial release mechanism.
The two treatments are medically distinct and should not be treated as interchangeable. Human growth hormone has specific approved indications and carries a different prescribing and monitoring profile.
GLP-1 medications such as semaglutide and tirzepatide primarily support weight loss by influencing appetite, satiety, gastric emptying, and glucose regulation. They can reduce both visceral and subcutaneous fat as total body weight decreases.
Tesamorelin works through growth hormone signaling and is more specifically associated with visceral fat. It is weight-neutral in its FDA-approved indication.
A GLP-1 may be the stronger choice for overall weight loss. Tesamorelin may be discussed when deep abdominal fat or body composition remains the central concern. Some qualified patients may use both within a carefully monitored program.
BPC-157 and TB-500 are generally considered for recovery and soft-tissue support. They do not share tesamorelin’s primary growth hormone pathway or its clinical evidence for visceral fat reduction.
Tesamorelin is the more relevant choice when abdominal fat and body composition are the main goals. A recovery peptide may be considered separately when training recovery or soft-tissue wellness is also a priority.
Tesamorelin works best inside a real medical plan. Increasing growth hormone and IGF-1 without appropriate screening, laboratory testing, or follow-up can create unnecessary risk and make it difficult to judge whether treatment is genuinely helping.
Led by board-certified plastic surgeon Sheila Nazarian, MD, Physique26 brings together medical weight management, body composition, aesthetics, and longevity-focused care in Beverly Hills.
Your treatment may include:
This is a medical plan with real follow-through. Every part of the protocol has a purpose, and continued treatment depends on measurable value.
If deep abdominal fat remains resistant despite consistent effort, tesamorelin may offer a more targeted approach. The first step is determining whether your concern involves visceral fat and whether growth hormone-releasing therapy fits your health profile.
Schedule a consultation with Physique26 in Beverly Hills to review your goals, laboratory needs, and treatment options.
Tesamorelin is not approved for general weight-loss management and is considered weight-neutral in its approved indication. It targets visceral abdominal fat rather than producing broad-scale weight reduction. Patients seeking significant overall weight loss may be better served by a GLP-1 program or another physician-guided strategy.
No. Tesamorelin is a growth hormone-releasing hormone analog. It signals the pituitary gland to increase the body’s own growth hormone production, which then raises IGF-1. It does not supply synthetic human growth hormone.
Both act through the GHRH pathway, but tesamorelin is generally more potent and longer-acting. Sermorelin is commonly selected for milder sleep, recovery, or lean-mass goals. Tesamorelin has stronger clinical evidence for reducing visceral abdominal fat.
Changes develop gradually. Some patients notice differences in waist measurements or clothing fit within a few months, while clinical studies often evaluate outcomes around six months. Results depend on treatment consistency, baseline visceral fat, metabolic health, and individual growth hormone response.
Some medically eligible patients may use tesamorelin alongside semaglutide, tirzepatide, or another GLP-1 medication. The treatments affect different pathways and serve different primary goals. Combination therapy requires coordinated prescribing, adequate nutrition, strength training, and laboratory monitoring.
Some clinicians combine them because tesamorelin acts through the GHRH receptor while ipamorelin acts through the ghrelin receptor. This may create a stronger growth hormone pulse, but combination therapy is not essential and has not been strongly proven to improve long-term outcomes. Your provider will determine whether the added complexity is worthwhile.
Testing commonly includes IGF-1, fasting glucose, and hemoglobin A1C. Your provider may order additional metabolic, hormonal, liver, kidney, or lipid testing based on your medical history and medications. Follow-up testing helps confirm that the treatment remains both useful and medically appropriate.
